Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study.
Folprecht, G Pericay, C Saunders, Mark P Thomas, A Lopez, R Roh, J Chistyakov, V Höhler, T Kim, J Hofheinz, R
Folprecht, G
Pericay, C
Saunders, Mark P
Thomas, A
Lopez, R
Roh, J
Chistyakov, V
Höhler, T
Kim, J
Hofheinz, R
Citations
Altmetric:
Abstract
The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC.
Description
Date
2016-04-18
Publisher
Collections
Keywords
Type
Article
Citation
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study. 2016: Ann Oncol